Login to Your Account

Rodin lands $27M to advance Alzheimer's program, but without exclusive Biogen deal

By Michael Fitzhugh
Staff Writer

Monday, September 18, 2017

Neuronal epigenetics specialist Rodin Therapeutics Inc. has completed a $27 million financing that will fund its soon-to-be-chosen lead histone deacetylase 2 (HDAC2) inhibitor through a phase Ib proof-of-concept study in Alzheimer's disease.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription